Marksans Pharma Merger & Restructuring Worth ₹9.64 Cr

Marksans Pharma Board Meeting Date

Marksans Pharma scheduled its Board meeting for November 4, 2026, to approve Q1/H1 unaudited results. No material decision has been taken yet.

Marksans Pharma Other Announcement

Periodic quarterly shareholding pattern filing for Marksans Pharma Ltd. This document provides the latest breakdown of shareholder categories as mandated by SEBI.

Marksans Pharma Promoter Selling (Off-Market)

Director Sandra Saldanha gifted 2,28,273 shares of Marksans Pharma Ltd to her daughters in an off-market transaction. This internal transfer reallocates promoter-group equity holdings.

Marksans Pharma Other Announcement

Marksans Pharma intimated shareholders about SEBI's extended special window (Feb 2026–Feb 2027) for re-lodgement of pre-April-2019 physical share transfer deeds. No new business, capital, or operational event is disclosed.

Marksans Pharma Annual General Meeting

Marksans Pharma Limited conducted its 34th Annual General Meeting on August 27, 2026. Shareholders considered the adoption of FY2025-26 financial statements and a dividend of Rs. 0.90 per share.

Marksans Pharma Other Announcement

Marksans Pharma Ltd. has received an ESG score of 56 from Crisil ESG Ratings & Analytics Ltd for Fiscal 2026.

Quint Digital Merger & Restructuring

Quint Digital's board approved a Rule 10b5-1 trading plan and the incorporation of a wholly owned overseas subsidiary. No investment amount was disclosed.

Hexaware Technologies Merger & Restructuring

Hexaware Technologies approved a slump sale of its step-down subsidiary Tech SMC Square India to Tech SMC Squared (GCC) India, a related-party deal. Consideration is cash, yet to be set by a registered valuer.

Execution

Expected completion by 30 June 2027; agreement date stated as 1 December 2026

Emkay Global Financial Services Merger & Restructuring Worth ₹2.75 Cr

Emkay Global agreed to sell its Wealth Management Business to a step-down subsidiary, Emkay Wealth Advisory, for Rs. 2.75 Crore cash. Completion is expected by 26 January 2027.

Value

₹2.75 Cr

Execution

Completion expected by 26 January 2027

TVS Holdings Merger & Restructuring

TVS Holdings forwarded TVS Motor's board outcome of October 28, 2026 approving acquisition of Harita ARC and a composite scheme of amalgamation and demerger. The scheme is subject to stock exchange, SEBI, NCLT and shareholder approvals.

Emkay Global Financial Services Merger & Restructuring Worth ₹30 Cr

Emkay Global approved transferring two subsidiaries to new subsidiary ECPL and slump-selling its wealth business. Up to Rs.30 Crore rights investment in ECPL was also approved.

Value

₹30.00 Cr

Execution

Divestment completion expected within 90 days of SPA execution, subject to regulatory approvals

Fortis Healthcare Merger & Restructuring Worth ₹277 Cr

Fortis subsidiary International Hospital acquired Suguna Ramaiah Hospitals' business, operations, land and building for Rs 277 Crore cash. The deal was consummated today, strengthening Bengaluru presence.

Value

₹277.0 Cr